Feb 10, 2023
January 25, 2025
This week’s newsletter included:
-
BioUtah on Capitol Hill
-
FDA 510(k) Clearance, CLIA-Waiver for Innovative BioFire® SpotFire® System and Respiratory Panel
-
Renalytix Announces a c.$20.3 Million Private Placement
-
Sumitomo Pharma Oncology Presented Preliminary Data From Phase 1 & 2 Clinical Study in Patients With Myelofibrosis at American Society of Hematology 2022 Annual Meeting
-
HOSA Judging Opportunity
-
100 Companies Championing Women Nomination Application
Featured New Member: Teva Pharmaceuticals
Recent News
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
- RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS
